New Mouse and Human Data Suggest GLP-1 Drugs May Slow Biological Aging

Key points

• A National Institutes of Health-funded study at the University of California, Berkeley, found that semaglutide extended the lifespan of older mice by more than what could be explained by calorie restriction alone.
• Eli Lilly reported that tirzepatide slowed biological aging by 0.7 to 1.1 years in a small group of older adults, with some biological clocks showing a reversal of up to four years.
• Novo Nordisk data suggests semaglutide reduced the biological age of the heart by two to four years and other organs by one to four years, with effects not fully explained by weight loss or blood sugar control.
• Researchers emphasize that it is too early to recommend these drugs for anti-aging purposes in healthy, non-obese individuals, as long-term effects and benefits in lean populations remain unknown.

Background

This development follows earlier reports in October 2026 that GLP-1 drugs showed promise as anti-aging agents, with initial data from Eli Lilly and Novo Nordisk suggesting they could reverse biological aging by two to three years. The current findings build on that by providing more detailed evidence from both animal and human studies, including a direct comparison between the effects of the drug and simple calorie restriction in mice.

How outlets are covering it

Yahoo Finance highlights the mouse study as a key breakthrough, suggesting the drugs' benefits may go beyond simple appetite suppression. CNN provides a more balanced view, noting that while the findings are exciting, experts like Dr. James Kirkland warn against overreading the data, especially for healthy individuals. CNN also points out that the human studies have limitations, such as the lack of a placebo group in some trials, and that the anti-aging effects may be primarily due to weight loss and blood sugar reduction.

Why it matters

If GLP-1 drugs are proven to slow aging in a broader population, it could transform the treatment of age-related diseases and potentially extend healthy lifespan. This could have significant implications for healthcare costs and public health strategies, but also raises questions about the ethical and practical implications of using these drugs for anti-aging purposes in healthy individuals.

What to watch

Further research is needed to determine the long-term effects of GLP-1 drugs on aging, particularly in healthy, non-obese individuals. Eli Lilly and Novo Nordisk are expected to continue their studies, with plans to follow participants for longer periods to see if the anti-aging effects persist or increase over time.